AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
trilostane 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 2746 | 13647-35-3 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
inhibits conversion of pregnenolone to progesterone; adrenal blocking agent used in treatment of Cushing's syndrome
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.36 | g | O |
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,CAMK2D,CDK5,EIF2AK3,ERBB2,GRK2,ITK,MAPK10,PDK1,PDK2,PDK4,PIK3CA,PRKDC,TEK | 14 | |||
| kinase-selectivity-class | EIF2AK3,GRK2 | 2 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| None | FDA | BIOENVISION |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | H02CA01 | SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS CORTICOSTEROIDS FOR SYSTEMIC USE ANTIADRENAL PREPARATIONS Anticorticosteroids |
| MeSH PA | D000019 | Abortifacient Agents |
| MeSH PA | D000021 | Abortifacient Agents, Steroidal |
| MeSH PA | D000970 | Antineoplastic Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D012102 | Reproductive Control Agents |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:50691 | abortifacient |
| CHEBI has role | CHEBI:50788 | EC 1.1.1.210 [3β(or 20α)-hydroxysteroid dehydrogenase] inhibitor |
Related Drugs by ATC class:
H02CA Anticorticosteroids 2 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Hypercortisolism | indication | 47270006 |
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Dogs | Hyperadrenocorticism caused by adrenocortical tumor | Indication |
| Dogs | Pituitary-dependent hyperadrenocorticism | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| VETORYL CAPSULES | Dechra, Ltd. | 1 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 7.75 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2 | Enzyme | INHIBITOR | DRUGBANK | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4020465 | VUID |
| N0000148218 | NUI |
| D01180 | KEGG_DRUG |
| 4020465 | VANDF |
| C0077144 | UMLSCUI |
| CHEBI:32260 | CHEBI |
| CHEMBL1200907 | ChEMBL_ID |
| DB01108 | DRUGBANK_ID |
| C009954 | MESH_SUPPLEMENTAL_RECORD_UI |
| 656583 | PUBCHEM_CID |
| 6850 | IUPHAR_LIGAND_ID |
| 3928 | INN_ID |
| L0FPV48Q5R | UNII |
| 152068 | RXNORM |
| 002119 | NDDF |
| 25142008 | SNOMEDCT_US |
| 387134000 | SNOMEDCT_US |
Pharmaceutical products:
None